| Hazard Information | Back Directory | [Description]
Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate. It contains a a protease-sensitive Val-Cit dipeptide, and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells. | [Uses]
Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization. | [IC 50]
Auristatin | [References]
[1] Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. DOI:10.1158/1078-0432.CCR-09-2069 |
|
|